Mirum(MIRM) - 2023 Q4 - Earnings Call Presentation

• Safety 27 PBC: Most Prevalent Cholestatic Liver Disease *Mirum market research Phase 2b Study of Volixibat in PBC Patients with Cholestatic Pruritus • Topline data to include pruritus, safety, and other secondary endpoints Primary Endpoint • Change in pruritus from Baseline to 28wk • Markers of disease and QoL • Markers of disease progression WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment • Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function whil ...